Pfizer's beleaguered obesity strategy has hit another setback as the pharma jettisoned its third and final GLP-1 agonist, citing poor data and tough competition. https://xmrrwallet.com/cmx.plnkd.in/gRfShWVR
Fierce Biotech
Information Services
New York, New York 103,293 followers
The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.
About us
Fierce Biotech is the dominant B2B news brand for the industry. Our focus daily is on biotech and medtech companies. We cover the drug and device development universe as well as the financing, deals, IPOs and M&A that happen along the way and the people who move biotech and medtech forward. Our coverage also feeds longer-form content, podcasts and events. Our journalists track the news closely and have developed a network of contacts to bring you exclusives. Our coverage runs the gamut from good news to bad and flattering to unflattering to give readers and listeners an unvarnished view of what’s truly happening. Delivering news, revealing insights straight to your inboxes: https://xmrrwallet.com/cmx.pfiercebiotech.questexinfo.com/loading.do?omedasite=LS_full. Our family of publications includes Fierce Biotech, Fierce Biotech PM Tracker, Fierce Medtech, Fierce Biotech Research, Fierce CRO, Fierce Life Sciences Weekly Digest and Fierce Cell & Gene Therapy. Follow our podcast ‘The Top Line’ on Apple Podcasts, Spotify, Amazon, iHeart or wherever you get your podcasts. We dig into high-impact trends and recount the week’s biggest headlines. For Pharma news you can’t miss: https://xmrrwallet.com/cmx.pwww.linkedin.com/company/fierce-pharma For Healthcare news you can’t miss: https://xmrrwallet.com/cmx.pwww.linkedin.com/showcase/fierce-healthcare
- Website
-
https://xmrrwallet.com/cmx.pwww.fiercebiotech.com/
External link for Fierce Biotech
- Industry
- Information Services
- Company size
- 51-200 employees
- Headquarters
- New York, New York
- Founded
- 2001
Updates
-
Frazier Life Sciences has gathered an impressive $1.3 billion in capital commitments for its 12th venture fund aimed at private early-stage biotechs. https://xmrrwallet.com/cmx.plnkd.in/guPqDf2U
-
Vinay Prasad has exited the FDA less than three months into the role as director of the CBER, overseeing vaccines and cell and gene therapies. https://xmrrwallet.com/cmx.plnkd.in/e9HEUJfe
-
Madrigal Pharmaceuticals is paying $120 million upfront for a preclinical GLP-1 receptor agonist that the biopharma plans to pair up with its approved fatty liver disease med Rezdiffra. https://xmrrwallet.com/cmx.plnkd.in/e9yiXiSn
-
Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027. https://xmrrwallet.com/cmx.plnkd.in/g4eZCEtM
-
Having recently scored approval for Nucala in chronic obstructive pulmonary disease, GSK has now signed a major $12 billion biobucks deal designed to strengthen the pharma’s offering for the respiratory condition. https://xmrrwallet.com/cmx.plnkd.in/g38n4u7B
-
Interested in learning how to implement PAT in your downstream process steps? A few CDMOs are ahead of the curve! Real-time, in-line process monitoring technology is the next major step in bringing Quality by Design (QbD) framework to pharmaceutical development, and AGC Biologics has adopted a process to successfully monitor in-line not only protein concentration but also excipients in a UF/DF process utilizing mid-infrared (MIR) spectroscopy. Discover how this leading CDMO enhances control of UF/DF steps that are crucial for the final drug substance formulation using PAT. Find a link to the case study in the comments section below. #Sponsored #Biopharmaceuticals #Pharma #Biotechnology #ProcessDevelopment #yourfriendlyCDMOexpert
-
The uncertainty around the future of Elevidys hasn’t destroyed Roche’s belief in the potential of gene therapies, the Swiss company’s head of pharma has told Fierce Biotech's James Waldron. https://xmrrwallet.com/cmx.plnkd.in/gaSA6GiF
-
Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor for inflammatory diseases over the line. https://xmrrwallet.com/cmx.plnkd.in/g826h-Up
-
A phase 3 study of AstraZeneca’s gefurulimab has hit its primary and all secondary endpoints, teeing up talks with regulators about the potential blockbuster generalized myasthenia gravis treatment. https://xmrrwallet.com/cmx.plnkd.in/dATwR6kK